Is double coverage of gram-negative organisms necessary?

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Gram-negative bacterial infections pose significant treatment challenges, with Pseudomonas aeruginosa infections often associated with high mortality.
• Empirical treatment strategies frequently involve combination antimicrobial therapy to ensure broad coverage and address potential resistance.
• Common justifications for combination therapy include synergistic effects, expanded spectrum of activity, and prevention of resistance.

Purpose of the Study:

• To examine the appropriateness of using combination antimicrobial therapy for infections caused by gram-negative organisms.
• To evaluate the clinical evidence supporting or refuting the routine use of combination therapy versus monotherapy.

Main Methods:

• Review of existing clinical data and studies comparing combination antimicrobial therapy with monotherapy for gram-negative infections.
• Analysis of evidence regarding specific drug combinations, such as beta-lactams with fluoroquinolones or aminoglycosides.

Main Results:

• No robust clinical data demonstrate improved patient outcomes with beta-lactam plus fluoroquinolone combination therapy compared to monotherapy.
• Evidence supporting the routine use of double antimicrobial coverage for gram-negative bacilli is lacking.
• Disadvantages include increased toxicity, higher costs, and a greater risk of superinfections.

Conclusions:

• Routine combination antimicrobial therapy for gram-negative infections is not supported by current clinical evidence.
• Combination therapy, particularly including an aminoglycoside, may benefit specific high-risk patients, such as those in shock or with neutropenia.
• Antimicrobial overuse contributes to antibiotic resistance, adverse effects, and increased healthcare costs.